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ONE OF THE BIOCHEMICAL MARKERS for
human and animal tumours is the accumu-
lation of certain ether lipids which may be
measured collectively as O-alkylglycerols
in the neutral lipids fraction (Snyder &
Wood, 1969). These lipids are increase(I in
a wide variety of neoplastic cells (Fried-
berg & Halpert, 1978) and malignant
tissues including human HCC (Snyder &
Snyder, 1975; Lin et al., 1978). Tumour
markers may be useful in the study of
possibly premalignant conditions. If they
are known to be early markers, their
appearance may confirm the characteriza-
tion of some conditions as cancerous.
Whilst little is known about the ether lipid
marker, it was reported to appear in rat
thymus long before leukaemia developed
in radiation-induced leukaemogenesis
(Brown et al., 1975). This report concerns
a search for the marker in liver tissue from
Chinese in Hong Kong who had both
hepatitis B infection and cirrhosis. The
reason for studying these cases was the
close statistical association between hepa-
titis B infection, macronodular cirrhosis
and HCC in the local population. HBsAg
was present in 3300 of liver biopsy speci-
mens from cases of HCC without cirrhosis,
and in 790 of those with both cirrhosis
and HCC (Wu, 1978). The possible con-
nection between hepatitis infection (often
with resulting cirrhosis) and HCC has been
noted among groups in North America,
Europe and Africa (Peters et al., 1977;
Bassendine et al., 1979; Blumberg et al.,
1975). Asian populations similarly affected
include the Japanese (Shikata et al., 1977),
Indians (Nayak et al., 1977) and Chinese
in Taiwan (Tong et al., 1971). The search
for the marker was therefore carried out
on liver tissue with both cirrhosis and
HBsAg. These tissues were grouped
according to the presence or absence of
HCC in the organ, on the supposition that
1CC might affect the metabolism of
residual liver tissue. Great care was exer-
cised in the selection of residual liver
specimens. Systematic naked-eye and
histological examinations of the tissues
were carried out in every case, and only
those specimens in which no tumour cells
wvere found were included in this study.
Our findings showed a difference in the
frequency with which the marker appeared
in liver tissue from organs with and with-
out HCC.
Tissuespecimens.-79 specimens were taken
at neeropsy, and 2 specimens of tumour-
bearing liver were obtained by partial hepa-
tectomy for HCC. The specimens represented
in Figs. 1 and 2 in columns I and II were
from patients wrho had no cancer ofany type,
but a variety of other diseases. Representa-
tive blocks were taken from each specimen
for histological examination. Tumour-bearing
liver was dissected under naked-eye ex-
amination into tumour and residual liver;
each specimen ofthe latter wa,s cut into 1-cm
slices, and only those portions free of tumour
foci selected. Blocks of these portions were
taken for microscopic examination, and the
specimen was analysed only if not a single
tumour cell in any block was seen; these
specimens were grouped in column III in the
Figs. The designation of specimens as HCC
(group IV, Fig. 2) wvas likewise based on
histology. All 81 specimens used for quanti-TUJMOUR MARKER IN HUMAN LIVER
tation of neutral O-alkylglycerolipids were
immersed in 10% neutral buffered formalin
for 22-24 h before lipid extraction.
Tissue histology.-Routine haematoxylin-
and-eosin-stained sections of the liver speci-
mens were examined. About 10-20 blocks
from each case wAere studied. The stage and
activity of cirrhosis were noted. Data on
liver-cell dysplasia were obtained using the
criteria outlined by Anthony et al. (1973).
HCC specimens showed either no clear cells,
or a focal or diffuse pattern of clear cells (Lai
et al. (in press).
Assays of HBsAg.-The presence or ab-
sence of hepatitis B antigenaemia was noted
from the clinical records, and where this had
not been analysed blood was obtained post
mor-tem for radioimmunoassay of HBsAg.
HBsAg in liver was assessed by Gomori's
aldehyde fuchsin stain and by immuno-
fluorescence (Wu & Lam, 1979). In a previous
study, we found that these histological
methods were sensitive indicators of HBsAg
status; HBsAg staining was occasionally
detected in liver cells from serologically
negative subjects (Ho et al. (in press)).
Blood and histological tests for HBsAg
showed complete concordance in all the
specimens examined in this study.
Biochemical methods. The procedures for
the colorimetric estimation of O-alkylgly-
cerols in the neutral lipids fraction, and the
gas-chromatographic analysis of O-alkyl-
glycerols have been given before (Lin et al.,
1977, 1978).
The histological basis for studying HB
antigenaemia and liver cirrhosis was the
frequency with which dysplasia was seen
in the tissues. Liver-cell dysplasia has
been characterized as a premalignant
change associated with liver-cell cancer
(Anthony et al., 1973). This view has been
supported by the finding of localized
ci-foetoprotein production in dysplastic
liver cells from patients with chronic liver
disease (Okita et al., 1977). Fig. 1 shows
the close association between liver-cell
dysplasia and HBsAg+ cirrhotic liver.
Dysplasia was present in 1/24 non-
cancerous liver specimens without HBsAg
or cirrhosis (Group I); in 13/16 HBsAg+
cirrhotic specimens within Group II, non-
cancerous liver; and in 16/19 specimens
of HBsAg+ cirrhotic specimens within
Group III, liver with HCC. The percentage
values in the 3 groups were respectively
4-2, 812 and 84-2. The differences be-
tween the first value and either of the
other two were significant at the 00005
level (X2 test). These results were similar to
the findings of Anthony et al. (1973) in
Ugandan Africans. Observations made on
a few cases which had only HBsAg or
cirrhosis are
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FIG. 1. Liver-cell dysplasia in cancerous and
non-cancerous liver affected by cirrhosis
and HBsAg. I and II, non-cancerous liver;
III, tissue with no tumour cells from liver
with HCC. 0, HBsAg-, no cirrhosis; *,
HBsAg+, with cirrhosis; A, HBsAg-, with
cirrhosis; A, HBsAg+, no cirrhosis. The
extent of cirrhosis in Groups II and III
was similar: slight in 25%, moderate ill
, 42% and severe in , 33%.
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not possible to determine, in this series of
cases, whether dysplastic changes were
the result ofhepatitis infection or cirrhosis,
since in 35/38 cases, HBsAg was accom-
panied by cirrhosis of the liver. A third
point is made in Fig. 1: liver-cell dys-
plasia did not appear more frequently in
Group III (17/23, 73.90%) than in Group II
(14/20, 700o). This difference was insignifi-
cant (X2 test). Dysplasia, in itself, did not
discriminate between liver with HCC and
non-cancerous liver.
Fig. 2 shows the levels of neutral 0-
alkylglycerolipids in the same group of
specimens. Also included in the Fig. are
values obtained in specimens of HCC
(Group IV). There was no difference in the
levels ofthese ether lipids between Group I
and the 16 specimens in Group II which
were both HBsAg+and cirrhotic (Student's
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FIG. 2. Tissue levels of neutral 0-alkyl-
glycerolipids in liver specimens grouped
according to the presence or absence of
HBsAg, cirrhosis and cancerous liver cells.
I and II, noncancerous liver, III, tissue with
no tumour cells from liver with HCC; IV,
HCC. The symbols are explained under
Fig. 1. The (lotted line represents the upper
(95 Oo) limit in non-cancerous liver: 1 2,ug/g.
t test). The means and s.d. were, respec-
tively, 0 44 + 0-38 and 0 49 + 0 43 Htg/g
wet weight of formalin-fixed tissue.
Accordingly, it was possible to set the
upper (95%o) limit in non-cancerous liver
as 1 2 tg/g, which was the mean+2 s.d.
of all values in Groups I and II. This limit
was exceeded in 7/24 specimens com-
prising Group III, and in 6/19 specimens
within this group which had both cirrhosis
and HBsAg. The probability associated
with either of these frequencies arising by
chance alone was less than 0 0005 (x2
test). We considered liver specimens with
concentrations above 1 2 Hg/g to have the
marker. The fact that some HCC speci-
mens had lower concentrations of neutral
0-alkylglycerolipids did not invalidate
their designation as tumour marker. The
level of these ether lipids was always
higher in the tumour, in the 17 pairs of
HCC and corresponding liver tissue which
were analysed in this study, and pre-
viously (Lin et al., 1978). The mean value
for all results in Group III was 0 97 + 1-2
,.g/g, which was significantly higher than
the mean of Groups I and II (0 45 + 0 38)
and lower than those in 1CC (8.8 + 9.9
,ug/g). The probabilities associated with
these two differences were both at the 0-01
level (variance-ratio test).
The observed changes could not be
attributed to differences in the total lipid
content of the various tissues, which were
about 30 mg/g in all 4 groups. Nor could
they be reasonably ascribed to the pre-
sence of tumour cells missed in the course
of histological examination. Several speci-
mens within Group III had neutral 0-
alkylglycerolipid levels representing 9-
15% of the levels found in their corres-
ponding tumours. The chances that micro-
scopic examination could have overlooked
1 cancer cell among 10 hepatocytes, or
even 1 in 7, were remote.
The view that some specimens in
Group III resembled HCC in respect of
these ether lipids was supported by
analysis of ether-linked side chains. This
type of analysis gave information on the
composition of the ether lipids in question,
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TABLE.-Altered composition of the ether-linked side chains in neutral glycerolipids from
liver specimens with the marker
Ether-linked side
Neutral 0-alkyl- chain in neutral Probability
glycerolipids glycerolipids of
Histological group (,ug/g) (C16:C18 ratio)* differencet
Non-cancerous liver without HBsAg or cirrhosis 1*2 0-24 + 0-12 (17) < 0 01 Non-cancerous liver with HBsAg and cirrhosis 41l2 0-33 + 0-32 (9) NS
HBsAg+, cirrhotic tissue with no tumour cells, f < 12 0.37 +024 (7) J <0.05
from liver with HCC > 1-2 0 56+0 53 (6) NS HCC with HBsAg and cirrhosis 0-5-23 0-80+0-48 (114 NS
* Ratio of hexadecylglycerol to octadecyl- plus octadecenylglycerol. Values are given as mean + s.d.
(no. of specimens).
t By variance ratio or Student's t test. NS, not significant.
t Difference from the second value in the column, P < 0-02; from the third value, P < 0-025.
and was therefore independent of the
measurement of ether lipid level. It was
found in a previous study that the ether-
linked side chains in HCC had more C16
and fewer C1s groups than non-cancerous
liver (Lin et al., 1978). We therefore
analysed most of the specimens in the
present series; the results are presented
in the Table. It was found, first ofall, that
slightly higher C16:C18 ratios were ob-
tained in non-cancerous liver with HBsAg
and cirrhosis, than in the same tissue with
neither of these factors. For this reason,
the further comparison of C16:C18 ratios
in Group III specimens could only be
made with HBsAg+, cirrhotic specimens.
Residual liver specimens without the
marker (i.e. with neutral O-alkylglycero-
lipids levels below 1 2 pg/g) had ratios not
different from those in non-cancerous
HBsAg+, cirrhotic liver. In contrast,
specimens with the marker had signifi-
cantly higher C16:C18 ratios, which were
in fact similar to those found in HCC.
These results showed that there was a
slight increase in C16:C18 ratios as the
result of the co-existing conditions of
hepatitis and cirrhosis, and a much larger
increase (seen in HCC) associated with
malignancy. Among the specimens within
Group III with hepatitis and cirrhosis,
specimens which had normal levels of the
ether lipids showed only a slight change;
those with high ether lipids levels showed
a further increase in the C16:C18 ratio. The
latter may be attributable to malignancy.
Since the tumour marker is defined by
an increase in the amount of neutral 0-
alkylglycerolipids, and not a change in the
composition of the ether-linked side
chains, the conclusions must be that the
marker was absent from non-cancerous,
HBsAg+, cirrhotic liver, and present in
some specimens of HIBsAg+ liver from
cases of 11CC. The positive finding in this
study was that the appearance ofthe ether
lipid marker in liver depended on the
presence of HCC in the same organ. This
could be explained in two ways: either the
ether lipids were secreted by the tumour
and taken up by the adjacent residual
tissues, or they were synthesized within
hepatocytes morphologically unlike cancer
cells.
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